GUJTHEMGujarat Themis Biosyn Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India and Japan. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • Overall evidence is weak (AlgoScore 38/100)
- • Valuation vs sector: P/E 75.4 vs sector 35.5
- • PEG ratio: 3.27
- • RSI: 37
- • MACD: bearish
- • Double Top bearish signal (setup quality 56%)
Bull case
- • Revenue growth: 22.1% YoY
- • Profit growth: 22.9% YoY
- • ROE: 16.2%
- • Golden cross setup: SMA50 above SMA200
Bear case
- • Valuation vs sector: P/E 75.4 vs sector 35.5
- • PEG ratio: 3.27
- • RSI: 37
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Momentum is fading versus the broader market
- • Valuation vs sector: P/E 75.4 vs sector 35.5
- • PEG ratio: 3.27
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹21.06). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.